October 1st 2023
Application of subretinal bevacizumab and tPA effectively removed subretinal hemorrhage secondary to nAMD, but anti-VEGF treatment must be continued.
September 29th 2023
September 12th 2023
September 12th 2023
September 10th 2023
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
Medical Crossfire®: What Strategies Can the Care Team Implement to Optimize the Management of Pediatric Patients with NF1?
View More
Advances In™ Pediatric Neuroblastoma: Exploring Current and Emerging Therapeutic Approaches for Relapsed/Refractory Disease and CNS Metastases
View More
Oncology Consultations®: Leveraging Clinical Data and Trials to Inform Treatment for Patients with PV
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
23rd Annual International Congress on the Future of Breast Cancer® West
Register Now!
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
Pharmacist-Led Interventions Can Improve HbA1c in Underserved Communities
September 29th 2023A study from UCLA suggests a pharmacist-led intervention contributed to improved HbA1c in Hispanic adults with type 2 diabetes management, underlining its potential to enhance outcomes in underserved populations.
AI-Powered Smartphone Applications Seen as Promising for Dermatologic Care Use
This new position statement by the Congress of the European Academy of Dermatology and Venereology identified several benefits to the implementation of technological innovations in dermatologic care.
International Group of HS Experts, Patient Research Partners Find Consensus on Evaluation Measures
This set of measures may promote a more accurate assessment of HS in patients as well as on their life outcomes, with the goal being shared decision-making in clinical practice.
FDA Approves Subcutaneous Vedolizumab for Moderate to Severe UC
September 28th 2023Data from the VISIBLE 1 trial showed more patients receiving subcutaneous vedolizumab achieved clinical remission, mucosal healing, durable clinical response, durable clinical remission, and corticosteroid-free clinical remission compared to those receiving placebo.